

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

DIBENZYLINE
(phenoxybenzamine)

Status: CVS Caremark Criteria

Type: Initial Prior Authorization with Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Dibenzylamine is indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. If tachycardia is excessive, it may be necessary to use a beta-blocking agent concomitantly.

Compendial Uses

Paraganglioma^{5,6}

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the treatment of pheochromocytoma or paraganglioma to control episodes of hypertension and sweating

AND

- The patient has experienced an inadequate treatment response to an alpha 1 selective adrenergic receptor blocker (e.g., doxazosin, prazosin, terazosin)

OR

- The patient has experienced an intolerance to an alpha 1 selective adrenergic receptor blocker (e.g., doxazosin, prazosin, terazosin)

OR

- The patient has a contraindication that would prohibit a trial of an alpha 1 selective adrenergic receptor blocker (e.g., doxazosin, prazosin, terazosin)

Quantity Limits apply.

360 capsules/25 days* or 1080 capsules/75 days*

*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

REFERENCES

1. Dibenzylamine [package insert]. Dublin 9, Ireland: Amdipharm Limited; April 2020.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2023; Accessed February 15, 2023.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed February 15, 2023.
4. Neumann HPH, Young WF, Eng C. Pheochromocytoma and Paraganglioma. *The New England Journal of Medicine* 2019;381:552-65.
5. Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. *Journal of Clinical Endocrinology and Metabolism* 2014;99(6):1915-1942.

6. Neuroendocrine and Adrenal Tumors. NCCN Guidelines version 2.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed February 15, 2023.